Steve Seedhouse
Stock Analyst at Cantor Fitzgerald
(4.52)
# 3,784
Out of 5,182 analysts
22
Total ratings
75%
Success rate
15.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | n/a | $40.95 | - | 4 | Apr 1, 2026 | |
| IRD Opus Genetics | Initiates: Overweight | $15 | $5.12 | +192.97% | 1 | Mar 30, 2026 | |
| SRZN Surrozen | Reiterates: Overweight | $40 | $29.95 | +33.56% | 2 | Mar 24, 2026 | |
| KRRO Korro Bio | Maintains: Overweight | $21 → $22 | $12.84 | +71.34% | 3 | Mar 13, 2026 | |
| HROW Harrow | Maintains: Overweight | $94 → $91 | $41.41 | +119.75% | 2 | Mar 4, 2026 | |
| BLTE Belite Bio | Maintains: Overweight | $200 → $266 | $163.06 | +63.13% | 2 | Mar 3, 2026 | |
| WVE Wave Life Sciences | Maintains: Overweight | $34 → $41 | $6.94 | +490.78% | 2 | Feb 5, 2026 | |
| XNCR Xencor | Maintains: Overweight | $40 → $42 | $13.10 | +220.61% | 2 | Nov 6, 2025 | |
| INVA Innoviva | Maintains: Overweight | $29 → $31 | $23.36 | +32.71% | 2 | Nov 6, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $7 | $4.44 | +57.66% | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $3.05 | +1,604.92% | 1 | Jul 11, 2025 |
Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Neutral
Price Target: n/a
Current: $40.95
Upside: -
Opus Genetics
Mar 30, 2026
Initiates: Overweight
Price Target: $15
Current: $5.12
Upside: +192.97%
Surrozen
Mar 24, 2026
Reiterates: Overweight
Price Target: $40
Current: $29.95
Upside: +33.56%
Korro Bio
Mar 13, 2026
Maintains: Overweight
Price Target: $21 → $22
Current: $12.84
Upside: +71.34%
Harrow
Mar 4, 2026
Maintains: Overweight
Price Target: $94 → $91
Current: $41.41
Upside: +119.75%
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $200 → $266
Current: $163.06
Upside: +63.13%
Wave Life Sciences
Feb 5, 2026
Maintains: Overweight
Price Target: $34 → $41
Current: $6.94
Upside: +490.78%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $40 → $42
Current: $13.10
Upside: +220.61%
Innoviva
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $31
Current: $23.36
Upside: +32.71%
Camp4 Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: $7
Current: $4.44
Upside: +57.66%
Jul 11, 2025
Initiates: Overweight
Price Target: $52
Current: $3.05
Upside: +1,604.92%